Thus far, it is known that the proliferator-activated receptor (PPAR)-β/δ can act as a transcription factor stimulating CerK gene transcription, and a PPAR-β/δ antagonist unveiled anti-tumor effects of PPAR-β/δ by attenuating progression and metastasis of melanoma [41]. Here, CERK is linked to neoplasm.